Spanish drugmaker PharmaMar has signed a licensing agreement with Boryung Pharm to commercialize the marine-derived anticancer drug Zepsyre (lurbinectedin), if approved, in South Korea. 7 November 2017
Japanese drugmaker Eisai says the China FDA has accepted its application to market Lenvima as a treatment for hepatocellular carcinoma (HCC). 7 November 2017
Tokyo’s Chugai Pharmaceutical has released new data from a Phase III study of Edirol, an active vitamin D3 derivative in development for the treatment of osteoporosis. 7 November 2017
Today, the US Food and Drug Administration approved a label extension of UCB’s anti-epilepsy drug Vimpat CV (lacosamide) as an oral option for patients four years and older with partial-onset seizures (POS). 6 November 2017
Tokyo’s Otsuka Pharmaceutical has presented detailed data from the Phase III REPRISE trial of tolvaptan in patients with ADPKD, the autosomal dominant, most common form of polycystic kidney disease. 6 November 2017
Patrick Vallance, president of pharmaceuticals R&D at UK pharma major GlaxoSmithKline, is set to leave the company to become the British government's new chief scientific adviser, a person familiar with the matter said on Friday, according to media reports by Reuters and others. 4 November 2017
Ireland incorporated Jazz Pharmaceuticals has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Vyxeos (daunorubicin and cytarabine) powder for concentrate for infusion to treat adults with high-risk acute myeloid leukemia (AML) defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). 3 November 2017
Japanese drug companies Shionogi and UMN Pharma have agreed to an alliance to research, develop and commercialize vaccines for the prevention of infectious diseases. 3 November 2017
US specialty drugmaker Mallinckrodt has entered into an agreement to acquire Ocera Therapeutics, a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for orphan and other serious liver diseases with high unmet medical need. 2 November 2017
US President Donald Trump's commission on combating drug addiction and the opioid crisis released its final report on Wednesday, according to CBS News and other media reports. 2 November 2017
A Phase III study of Dupixent (dupilumab) in severe, steroid-dependent asthma met not only the primary endpoint but also two key secondary endpoints, Sanofi and Regeneron have announced. 1 November 2017
Amazon has secured approval to become a wholesale drugs distributor in at least 12 states, fuelling speculation that the online retail giant is moving closer to becoming a pharmacist. 1 November 2017
Germany’s Bayer and New Jersey, USA-based Johnson & Johnson have won European approval for an extended label for oral Factor Xa inhibitor Xarelto. 1 November 2017
East Coast rare disease and oncology specialist ArQule has been awarded rare pediatric disease designation for its Proteus syndrome candidate miransertib (ARQ 092). 1 November 2017
Shanghai Fosun Pharmaceutical Group, one of China’s top drugmakers, has entered into an agreement to acquire all the shares in French drug distributor Tridem for 63 million euros ($73 million), as it continues its aggressive expansion into overseas markets. 31 October 2017
Allergan has received an Imported Drugs License (IDL) from the Chinese Food and Drug Administration (CFDA) to market Ozurdex (dexamethasone intravitreal implant 0.7mg) for the treatment of adult patients with macular edema following either branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). 30 October 2017
US modified-release drug delivery specialist Neos Therapeutics today announced that its board of directors has unanimously rejected the October 26 unsolicited proposal from PDL BioPharma to acquire all of the outstanding shares of Neos for $10.25 per share in cash. 30 October 2017
Switzerland’s Novartis has announced positive data from the Phase III PARADIGMS study into Gilenya versus current standard of care as a treatment for multiple sclerosis . 30 October 2017
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024